-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $88

Benzinga·12/09/2025 16:46:24
語音播報
Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $80 to $88.